Key catalysts approach for Orphazyme, Gemini and Immutep.
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.